Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Pharmacokinetic Models: Comparison and Selection Criterion

Pharmacokinetic Models: Comparison and Selection Criterion

Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

Preclinical Development: Overview

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

Pharmacodynamic Models: Overview

Pharmacodynamic Models: Overview

Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...

Pharmacokinetic Models: Overview

Pharmacokinetic Models: Overview

Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Concise Guide to PHARMACOLOGY 2025/26: G protein-coupled receptors.

British journal of pharmacology·2025

Same author

Navigating Solute Carrier Transporters-A Comprehensive Review of Functionalized Small Molecule Probes for Target Identification and Characterization.

Medicinal research reviews·2025

Same author

The solute carrier superfamily interactome.

Molecular systems biology·2025

Same author

Covalent functionalization of G protein-coupled receptors by small molecular probes.

RSC chemical biology·2025

Same author

Stereochemical optimization of <i>N</i>,2-substituted cycloalkylamines as norepinephrine reuptake inhibitors.

RSC medicinal chemistry·2024

Same author

Labeling of CC Chemokine Receptor 2 with a Versatile Intracellular Allosteric Probe.

ACS chemical biology·2024

Search research articles

Related Experiment Video

Updated: May 27, 2026

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

Which compound to select in lead optimization? Prospectively validated proteochemometric models guide preclinical

Gerard J P van Westen¹, Jörg K Wegner, Peggy Geluykens

¹Division of Medicinal Chemistry, Leiden/Amsterdam Center for Drug Research, Leiden, The Netherlands.

|December 2, 2011

Summary

This summary is machine-generated.

This study introduces proteochemometric modeling to predict HIV drug effectiveness against various viral mutants. This approach aids in selecting the best drug candidates early in preclinical development for personalized HIV therapy.

More Related Videos

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Related Experiment Videos

Last Updated: May 27, 2026

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Area of Science:

Computational chemistry
Drug discovery
Virology

Background:

Drug resistance from target variability is a major challenge in treating diseases like HIV.
Identifying effective drugs against diverse HIV strains, including mutants, remains difficult.

Purpose of the Study:

To apply proteochemometric modeling for predicting the performance of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) against HIV Reverse Transcriptase (RT) mutants.
To support preclinical drug development by enabling accurate lead selection for individual HIV strains.

Main Methods:

Developed proteochemometric models using both small molecule and target (14 HIV RT mutants) properties.
Validated model predictions by experimentally testing 317 compound-mutant pairs.
Assessed prediction accuracy based on mutant similarity to the training set.

Main Results:

Achieved a prediction error (RMSE 0.62) comparable to experimental assay variability.
Demonstrated high accuracy in predicting effective compounds for previously uncharacterized HIV mutants.
Successfully identified promising drug leads for specific viral genotypes.

Conclusions:

Proteochemometric models effectively predict compound performance against diverse HIV mutants.
This approach facilitates the selection of optimal drug candidates for preclinical development.
The modeling strategy is adaptable for other targets with genetic variability, such as other viruses, bacteria, or GPCRs.